Eupraxia Pharmaceuticals (EPRX) Receivables (2023 - 2025)

Eupraxia Pharmaceuticals (EPRX) has reported Receivables for 4 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables rose 185.52% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (up 185.52% YoY), while the FY2025 annual figure was $1.4 million, up 185.52% from the prior year.
• Receivables grew to $1.4 million in Q4 2025 per EPRX's latest filing, from $486946.0 in the prior quarter.
• Across five years, Receivables topped out at $1.4 million in Q4 2025 and bottomed at $103607.0 in Q4 2022.
• Historically, Receivables has averaged $581308.8 across 4 years, with a median of $415653.5 in 2023.
• Annual changes were most pronounced in 2023 — Receivables jumped 232.37% — and 2024, when it jumped 41.41%.
• Eupraxia Pharmaceuticals' Receivables stood at $103607.0 in 2022, then surged by 232.37% to $344361.0 in 2023, then surged by 41.41% to $486946.0 in 2024, then jumped by 185.52% to $1.4 million in 2025.
• Business Quant data shows EPRX's Receivables at $1.4 million in Q4 2025, $486946.0 in Q4 2024, and $344361.0 in Q4 2023.